Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 7/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | EBP | Q15125 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9705574 | 0.91 | CA2 (0.52) | CA2SIGMAR1EBPTMEM97PRSS1 | |
| SCHEMBL3077526 | 0.87 | BIRC5 (0.47) | RENMAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL88960 | 0.85 | CA2 (0.48) | RENCA2MAPTSIGMAR1EBP | |
| SCHEMBL6801155 | 0.85 | SIGMAR1 (0.51) | CA2SIGMAR1EBPTMEM97 | |
| SCHEMBL9706259 | 0.84 | CA2 (0.52) | CA2NPC1MAPTHPGDRAB9A | |
| SCHEMBL3081718 | 0.83 | SLC6A4 (0.50) | RENNPC1MAPTHPGDRAB9A | |
| SCHEMBL2810242 | 0.83 | REN (0.48) | RENCA2NPC1MAPTHPGD | |
| SCHEMBL15173216 | 0.83 | TTR (0.50) | RENCA2PRSS1 | |
| SCHEMBL15173349 | 0.83 | CA2 (0.47) | RENCA2NPC1MAPTHPGD | |
| SCHEMBL29521379 | 0.83 | REN (0.48) | RENCA2NPC1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011148392-A1 | PROCESS FOR THE PREPARATION OF (2S,4S,5S,7S)-N-(2-CARBAMYL-2- METHYLPROPYL)-5-AMINO-4-HYDROXY-2,7-DIISOPROPYL-8-[4-METHOXY-3-(3- METHOXYPROPOXY)PHENYL]-OCTANAMIDE HEMIFUMARATE AND ITS INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2011-12-01 | — | — | WO | claimed |
| WO-2018154466-A1 | DIHYDROQUINOLIZINONES AS ANTIVIRALS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-30 | — | — | WO | disclosed |
| US-9079839-B2 | Methods for preparation of pharmaceutical intermediates of aliskiren | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2015-07-14 | — | — | US | disclosed |
| US-9079839-B2 | Methods for preparation of pharmaceutical intermediates of aliskiren | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2015-07-14 | — | — | US | disclosed |
| US-20130231509-A1 | METHODS FOR PREPARATION OF PHARMACEUTICAL INTERMEDIATES OF ALISKIREN | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2013-09-05 | — | — | US | disclosed |
| US-20130231509-A1 | METHODS FOR PREPARATION OF PHARMACEUTICAL INTERMEDIATES OF ALISKIREN | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2013-09-05 | — | — | US | disclosed |
| US-8362040-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-8362040-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-8362040-B2 | 4-phenylpiperidine derivatives as renin inhibitors | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| WO-2012078147-A1 | A PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE PRODUCTION OF ALISKIREN | WATSON LABORATORIES, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2003103653-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE USING ARYL ALKANOIC ACID AMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| EP-0678503-B1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | NOVARTIS AG (CH) | 1999-09-01 | — | — | EP | disclosed |
| US-5705658-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-01-06 | — | — | US | disclosed |
| US-5659065-A | CHEMICAL INTERMEDIATES FOR MEDICINAL ACTIVE AGENTS | NOVARTIS CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| US-5654445-A | INTERMEDIATES FOR RENIN INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5646143-A | FOR TREATING A VARIETY OF CONDITIONS | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627182-A | RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS | CIBA GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0678503-A1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| EP-0678500-A1 | Alpha-amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231509-A1 | METHODS FOR PREPARATION OF PHARMACEUTICAL INTERMEDIATES OF ALISKIREN | VRK2, VRK1, LPXN | REN 113/4885CA2 967/4885NPC1 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.